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Activation of protein kinase C reduces thromboxane receptors
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Department of Medicine, VA Medical Center and University of Pittsburgh, Pittsburgh, Pennsylvania, USA
Activation of protein kinase C reduces thromboxane receptors in
glomeruli and mesangial cells. The potential role of protein kinase C
(PKC) in the modulation of thromboxane A2 (TX) receptor density was
evaluated in intact glomeruli and cultured renal mesangial cells (MC)
from the rat. Incubation of glomeruli with 0.1 sM phorbol dibutyrate
(PDBu) or 30 m glucose for four hours activated PKC as reflected by
increased in situ phosphorylation of the 80 kDa MARCKS protein, a
specific endogenous substrate for PKC. High affinity binding to TX
receptors, as assessed from the binding of the stable TX antagonist
[3H]-Sq-29548 (Sq), was decreased 30% in glomeruli exposed to PDBu
and 28% in glomeruli incubated in 30 m D-glucose for four hours.
Concurrent incubation with 0.05 /LM of the PKC inhibitor staurosporine
blocked both MARCKS protein phosphorylation and the decrease in
TX receptor sites in response to either PDBu or 30 m glucose. Neither
30 mrs L-glucose nor 30 mat mannitol altered glomerular PKC activity
or TX receptor density, thus excluding an osmotic effect of D-glucose,
and implicating cellular metabolism of glucose in the expression of
these actions. Inhibition of endogenous production of TX with indo-
methacin during exposure of glomeruli to 30 m glucose did not prevent
the decrease in TX binding. Homologous down-regulation of TX
receptors mediated by endogenous TX was therefore not implicated in
this action of glucose. The affinity of the glomerular receptor sites for
['HI-Sq was not affected by PKC activation. MC in passages 3 to 7 also
demonstrated high affinity sites for ['HI-Sq (Kd, 2.8 nM). Culture of MC
with PDBu (0.05 or 0.1 M) for four hours decreased TX receptor
density. In response to 0.1 sM PDBu, TX receptor density declined
from 15 to 10 fmol/106 cells. These studies demonstrate that PKC
activation is linked to down-regulation of TX receptor sites in both
glomeruli and MC. They suggest that the down-regulation in glomerular
TX receptor sites observed in early diabetes in the rat may likewise be
related to the concurrent activation of glomerular PKC previously
demonstrated in that model.
Glomerular hyperfiltration is a characteristic of early diabetes
mellitus in both humans and experimental animals, and has
been implicated in the subsequent development of diabetic
nephropathy [1]. Multiple factors may contribute to the patho-
genesis of glomerular hyperfiltration in diabetes. They include
changes in the circulating and local concentration of vasoactive
agents, and changes in the responsiveness of the renal vascu-
lature or glomeruli to these agents [2]. Among the factors
implicated in the mediation of glomerular hyperfiltration in the
streptozotocin diabetic rat (SDR) model is glomerular produc-
tion of eicosanoids, which are increased early in the course of
diabetes [3, 4]. Glomerular hyperfiltration in SDR is attenuated
by cyclooxygenase inhibitors despite the fact that glomerular
production and urinary excretion of both the vasodilatory
prostanoids (PG!2 and PGE2) and the potent vasoconstrictor
thromboxane A2 are clearly enhanced in early diabetes [3]. A
factor which may contribute to the apparent dominant effect of
enhanced production of vasodilatory prostanoids early in dia-
betes in SDR was identified by the recent work of Wilkes et al
[5]. These studies demonstrated a decrease in thromboxane
(TX) glomerular receptor density in the one to two week SDR
that was associated with an attenuation of the vasoconstrictor
response to U-466l9, a stable TX/PG endoperoxide analog [5].
The mechanism which mediates the decline of glomerular TX
receptor density early in diabetes is not known. However,
previous studies in our laboratory have demonstrated that the
protein kinase C (PKC) system is activated in glomeruli from
one to two week SDR [6]. Activation of glomerular PKC in
diabetes is attributable at least in part to increased glomerular
generation of the endogenous PKC agonist diacyiglycerol which
is formed by de novo synthesis from glycerophosphate in the
presence of a high ambient glucose concentration [7]. PKC
activation has recently been implicated in the down-regulation
of receptors to several pressor hormones, including angiotensin
11(8], vasopressin [9] and endothelin [10]. Moreover, in gb-
meruli isolated from SDR, the density of low affinity receptors
for endothelin is decreased, and this change is reversed by
treatment of rats with a PKC inhibitor [11]. Based on these
observations, we examined the possibility that TX receptor
density in glomeruli isolated from normal rats and cultured rat
mesangial cells (MC) may also be modulated by the PKC
system. Our results demonstrate that activation of PKC in-
duced either by phorbol ester or a high ambient concentration
of glucose is associated with a rapid reduction in the number of
TX receptors in isolated glomeruli and MC, and that the decline
in TX receptor density induced by these agents is prevented by
an inhibitor of PKC.
Methods
Glomerular isolation, incubation and receptor binding studies
Received for publication November 9, 1992
and in revised form February 9, 1993
Accepted for publication February 11, l99,
© 1993 by the International Society of Nephrobogy
58
Glomeruli were prepared from the kidneys of 180 to 200 g
female Sprague-Dawley rats by the graded sieving method as
previously described [31. Gbomeruli retained on the 75 j. sieve
were decapsulated by passage through a 25 gauge needle twice
[12], and incubated in Krebs-Ringers bicarbonate glucose buffer
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(KRBG) containing 1 mg/mi fatty acid free bovine serum
albumin under an atmosphere of 95% 02/5% CO2. Additions of
test agents were made as noted in the figure legends. Incuba-
tions were terminated after four hours by washing the glomeruli
three times with Tris buffered saline (0.9% NaCl, 50 mrvi
Tris-HCI, pH 7.4, TBS) at 4°C. In some experiments indicated
in the Results, 10 M indomethacin was included in the medium
to prevent endogenous synthesis of TX and other eicosanoids
which might independently down-regulate the TX receptor. The
concentration of indomethacin employed suppressed media
TXB2 and PGE2 to undetectable levels, as assessed by radio-
immunoassay methods previously reported in detail [31.
TX receptor binding studies, density, and affinity were ex-
amined from the binding of the stable TX antagonist Sq-29548
(lS[la,2n(SZ), 3,4j)-7-[3-[2-Phenylamino-carbonyl1hydrazi-
nojmethyi]-7-oxabicylclo[2.2. l]-hept-2-yl]-S-heptenoic acid) as
previously described by Wilkes et al [13]. Briefly, glomeruli
were resuspended in TBS containing 0.5 to 40 flM (saturation
binding experiments) or 10 nM [3H]-Sq 29548 (Sq), 0.2 ml
aliquots placed in polyethylene tubes, and incubated with
mixing at 25°C for 25 minutes. Preliminary studies showed that
[3H]-Sq binding was maximal by 15 minutes and remained
constant for 45 minutes. Nonspecific binding was determined in
the presence of 50 LM non-radioactive Sq and was 15 to 35% of
total binding. Specific binding data, defined as total binding
minus non-specific binding, are presented. After incubation,
glomeruli were harvested by filtration (Gelmann Type AlE glass
fiber filters) and washed three times with 4 ml 4°C TBS. The
filters were dried, and the bound radioactivity determined by
liquid scintillation counting. Data are expressed as a function of
glomerular protein determined by the method of Bradford [14].
Glomerular MC isolation, culture, and TX receptor binding
studies
MC lines were established from rat glomeruli as previously
described [15]. Preliminary studies indicated that Sq binding to
MC was stable from passages 3 to 7 but diminished after
passage 8. Therefore, passages 3 to 7 were used for these
studies. MC were maintained in RPMI-l640 medium containing
15% FCS, 100 U/ml penicillin, 100 p.g/ml streptomycin, 5 sg/ml
insulin, 5 g/ml transferrin, and 5 ng/ml sodium selenite at 37°C
in an atmosphere of 5% C02, 95% air. Consistent with the
report of Dorn and Becker [16] that culture of vascular smooth
muscle cells with serum resulted in down-regulation of TX
receptor sites, preliminary studies of cultured MC demon-
strated that reduction in the concentration of FCS from 15% to
1% for 24 or 48 hours resulted in increased specific binding of
Sq from 5.3 to 14.0 fmol/mg protein. Accordingly, MC were
grown to confluence in 24 well plates and the serum concentra-
tion of the media was decreased to 1% for 24 hours before Sq
binding was evaluated.
To evaluate the effects of PKC activation on TX receptor
density in MC, cells were washed three times with phosphate
buffered saline (PBS). The medium was changed to RPMI-1640
containing 1 mg/ml BSA and phorbol dibutyrate (PDBu) or
vehicle as noted, and incubation continued for four hours. This
medium was removed, the cells washed three times with PBS,
and RPMI-1640 containing 1 mg/mI BSA and concentrations of
[3H]-Sq-29548 ranging from 0.05 to 25 n added. Binding
equilibrium was attained by 20 minutes and maintained through
45 minutes of incubation at 37°C (data not shown). Accordingly,
Sq binding was routinely assessed in MC after a 30 minute
incubation at 37°C. Nonspecific binding was determined in the
presence of 50 jsM unlabeled Sq-29548, and ranged from 5% to
35% of the total. The incubation was terminated by washing the
cell layers three times with TBS at 4°C and the cells solubilized
in 1.0 N NaOH. Aliquots of MC were taken for determination of
protein by the Bradford method [14] and quantitation of bound
[3H]-Sq by liquid scintillation counting. Cell number was deter-
mined from wells subjected to the same washing and media
changes, followed by addition of trypsin. Binding affinity (Kd)
and maximum number of binding sites (Bmax) were determined
from Scatchard analysis of the binding data.
Assessment of PKC activity
Glomeruli were prepared and MC cultured as described for
studies of TX binding. PKC activation was determined by the in
situ phosphorylation of the 80 kDa, MARCKS protein, a
specific endogenous substrate for protein kinase C, as previ-
ously described [15]. Briefly, MC were washed two times with
phosphate free KRBG, and incubated in phosphate free RPMI
containing 30 sCi/ml [32P]-orthophosphate for four hours.
PDBu or the dimethysulfoxide (DMSO) vehicle of PDBu was
present for four hours or the final 15 minutes of labeling, as
noted in the figure legends. Endogenous phosphorylation was
terminated by washing the MC monolayers with KRBG con-
taining 2 m phosphate. The acid soluble, 80 kDa protein was
extracted and separated electrophoretically on 9% SDS/poly-
acrylamide gels. In situ phosphorylation was quantitated by
densitometry of autoradiograms of the gels. The results were
expressed as the ratio of the density of the 80 kDa band with
respect to a reference band of 40 kDa.
Isolated glomeruli were treated similarly. After incubation
with [32P]-orthophosphate, the glomeruli were centrifuged for
one minute at 12000 x g and the medium removed. They were
washed once with PBS and homogenized with a hand held
pestle in microfuge tubes in 2.5% PCA containing 1 mM
phenylmethylsulfonyl fluoride. The homogenates were centri-
fuged, and the phosphorylated proteins in the acid-soluble
extract separated by electrophoresis and quantitated, as with
the MC extracts. In both MC and glomeruli, phosphorylation of
the 40 kDa reference band was stable under all conditions of
incubation shown. For example, the ratio of 40 kDa phospho-
rylation in glomeruli exposed to test agents versus vehicle did
not differ from unity: ratio of PDBu versus control, 1.03 0.06
(N = 4); 30 m glucose versus control, 0.96 0.04 (N = 4); and
0.05 LM staurosporine versus control, 1.01 0.12 (N = 4).
Analogous stability of 40 kDa phosphorylation in MC exposed
to these test agents was also observed, as previously reported
[15]. Figure 1 is a representative autoradiogram showing the
electrophoretic separation of the 80 kDa MARCKS protein
from the 40 kDa reference band, and the increase in 80 kDa
relative to 40 kDa protein phosphorylation in response to PDBu
(lane 3) and high glucose (lane 2). As previously reported [15],
the 80 kDa protein phosphorylated was specifically identified as
the MARCKS protein by immunoprecipitation with polyclonal




Fig. 1. Effects of 30 mM D-g!ucose and 0.1 /.LM PDBu on MARCKS
protein phosphory/ation in glomeruli. Glomeruli were isolated, incu-
bated with agonist or vehicle for four hours, and extracts subjected to
SDS-gel electrophoresis and autoradiography as described in Methods.
Lane I, extract from control glomeruli; Lane 2, extract from glomeruli
exposed to 30 m glucose, Lane 3, extract from glomeruli exposed to
0.1 /SM PDBu. Arrow indicates 80 kDa MARCKS protein.
Statistics
All experiments were performed at least three times. In a
single experiment [3H]-Sq specific binding was determined from
triplicate wells of MC or three aliquots of a single glomerular
preparation. For purposes of statistical analysis, the average of
replicate determinations for each incubation condition in a
single experiment was entered as one value. Analysis of van-
ance (ANOVA) was performed to compare multiple groups.
The significance of differences between any two average values
was determined by the independent Student's t-test.
Materials
[3H]-Sq, 30 Cllmmol was obtained from New England Nu-
clear (Boston, Massachusetts, USA). Nonradioactive Sq was a
gift from the Squibb Institute for Medical Research (Princeton,
New Jersey, USA). PDBu, 4-phorbol 12, 13-didecanoate (PDd),
and staurosporine were obtained from Sigma Chemical Co. (St.
Louis, Missouri, USA). Sources for other reagents have been
previously reported [8, 15].
Results
Incubation of glomeruli with 0.1 jiM PDBu resulted in an
increase in the phosphorylation of the PKC specific 80 kDa
substrate which was evident within 15 minutes (Fig. 2). The
increase in phosphorylation of the 80 kDa MARCKS protein
induced by PDBu was sustained for four hours, and at that time





Kd nM fmol/103 glomeruli fmol/mg protein
Glomeruli
Vehicle 6.4 1.0 26 3 387 38
0.1 jiM PDBu 6.1 0.7 18 1.? 270 22
fmol/l06 cells fmol/mg protein
Renal mesangial cells
Vehicle 2.82 0.38 15.0 1.1 27 2
0.1 jiM PDBu 2.84 0.31 10.2 0.5a 20 ia
In contrast, the non-tumor-promoting phorbol ester 4-phorbol
12, 13-didecanoate (PDd) did not activate PKC as evaluated by
in situ phosphorylation (Fig. 1). As is also shown in Figure 2,
the PKC inhibitor staurosporine (0.05 sM) blocked the increase
in 80 kDa phosphorylation induced by PDBu when added 30
minutes prior to this PKC agonist.
As previously reported [131, isolated glomeruli show specific,
high affinity binding of the TX antagonist Sq to a single site.
Scatchard analysis of binding over the range of 0.05 to 40 nM Sq
gave a Kd of 6.4 1,0 nM and Bmax of 387 38 fmol/mg protein
or 26 3 fmol/103 glomeruli (Table 1). Incubation of glomeruli
with 0.1 p.M PDBu for four hours did not affect the affinity of the
receptor for Sq; the Kd in phorbol ester-treated glomeruli was
6.1 0.7 flM. However, the Bmax was significantly depressed by
PDBu whether it was expressed on the basis of glomerular
number or protein content (Table 1). As shown in Figure 3,
specific binding of [3H]-Sq to glomeruli exposed to PDBu for
four hours was decreased by 31%. No changes in binding were
observed at 15 minutes or one hour after PDBu (not shown).
Incubation of glomeruli with the PKC inhibitor staurosporine
alone had no significant effect on Sq binding. However, addition









Fig. 2. Effects of PDBu on 80 kDa protein phosphorylation in glomer-
33 uli. Isolated glomeruli were incubated as described in Methods. Ago-— fists shown were present for the final 15 minutes of incubation; 0.05 jiM
staurosporine (SS) was added 30 minutes before PDBu. PDd = 4-phor-
bol 12,13-didecanoate. Values shown are mean SE of data from 3 to
24-.. 5 experiments. < 0.05 when compared to the DMSO vehicle alone.
Table 1. Effect of PDBu on [3HJ-Sq-29548 binding to glomeruli and
renal mesangial cells
1 2 3
Vehicle 0.1 tM 0.05
.LM PDBu + 0.1 IIM
PDBu SS SS PDd
B max
Glomeruli or mesangial cells were exposed to 0.1 jiM PDBu or 0.1%
DMSO for four hours, washed, and [3H]-Sq binding determined as
described in Methods. Results shown are mean SE of values from
three separate experiments.























Vehicle 0.1 .tM 0.05 JIM PDBu +
PDBu SS SS
Fig. 3. Effects of PDBu on thromboxane receptor density in isolated
glomeruli. Glomeruli were incubated with phorbol dibutyrate (PDBu),
phorbol didecanoate (PDd), or staurosporine (SS) for four hours,
washed, and specific binding of [3H]-Sq to thromboxane receptor sites
evaluated as described in Methods. Binding studies were conducted at
10 nM Sq. Data are corrected for non-specific binding. Values shown
are mean SE of data from 4 to 6 experiments. < 0.05 vs. the DMSO
vehicle alone.ilil
Fig. 4. Effect of medium glucose concentration on 80 kDa protein
phosphorylation in isolated glomeruli. Incubations were conducted for
15 minutes (LI) or 4 hours () after addition of glucose. Where
indicated, 0.05 /.LM staurosporine (SS) was added 30 minutes prior to
increasing the medium glucose concentration. Values shown are mean
SE of data from 4 to 6 experiments; *fJ < 0.05 vs. 5 mM glucose.
of 0.05 /M staurosporine 30 minutes before addition of PDBu
prevented the decrease in Sq binding induced by PDBu. PDd,
which did not activate PKC (Fig. 2), failed to alter Sq binding to
glomeruli.
Figure 4 shows the effects of a 15 minute or four hour
exposure to different concentrations (5 to 30 mM) of media
glucose on glomerular PKC activity. Compared to values ob-
served with 5 m glucose, glomerular 80 kDa protein phospho-
rylation was significantly increased by a 15 minute exposure to
10, 20 or 30 m glucose. However, after four hours, only
glomeruli incubated in 30 m glucose showed a sustained
increase in PKC activity as assessed from 80 kDa phosphory-
lation. Staurosporine, added 30 minutes before the incubation
of glomeruli for four hours with 30 mrvi D-glucose prevented the
action of D-glucose to enhance 80 kDa phosphorylation. In
contrast to D-glucose, neither 30 mti L-glucose (Fig. 4) nor 30
mM mannitol (not shown) altered 80 kDa phosphorylation.
As shown in Figure 5, Sq binding to glomeruli tended to vary
inversely with media glucose concentration. However, only the
Fig. S. Effects of medium glucose concentration on thromboxane
receptor density in isolated glomeruli. Glomeruli were incubated with
the glucose concentration shown for 4 hours. Indomethacin l0 M ()
was present for 4 hours where noted. Where indicated, 0.05 zM
staurosporine (L) was added 30 mm prior to increasing the medium
glucose concentration. (D) = 25 m L-glucose. Values are mean SE
of data from 4 to 6 experiments; P < 0.05 vs. 5 m glucose.
Sq binding observed when glomeruli were incubated with 30
m glucose was significantly lower (25%) than values at 5 mrt
glucose. No changes in Sq binding were observed after 15
minutes and one hour exposures to 30mM glucose (not shown).
As is also shown in Figure 5, inclusion of 10 M indomethacin
in four-hour glomerular incubates did not alter the decline in TX
receptors induced by 30 m glucose. Similarly, in glomerular
incubations conducted for 24 hours, indomethacin did not
prevent the 50% decline in TX receptor number induced by 30
m glucose (indomethacin alone, [3H]-Sq binding 402 18
fmol/mg protein; indomethacin + 30 m glucose = 206 61, N
= 3, P < 0.01). These results provide evidence against the
possibility that the fall in TX receptors in response to glucose
was induced by increased glomerular TX production and con-
sequent homologous down-regulation. As is also shown in
Figure 5, addition of 0.05 LM staurosporine blocked the reduc-
tion in Sq binding induced by 30 mt D-glucose. Incubation of
glomeruli for four hours with either 30 mM L-glucose (Fig. 5) or
30 mM mannitol (not shown) failed to alter Sq binding to
glomeruli.
Specific, high-affinity binding sites for Sq were also identified
in cultured rat MC. MC incubated with PDBu for four hours
showed a dose dependent increase in PKC activity as measured
by in situ phosphorylation of the 80 kDa substrate (Fig. 6A)
which was paralleled by a decrease in the number of binding
sites for Sq (Fig. 6B). Quantitatively, there was a much larger
increase in 80 kDa phosphorylation than decrease in TX recep-
tor sites. The precise quantitative relationship, if any, between
PKC mediated phosphorylation of the 80 kDa MARCKS pro-
tein and down-regulation of TX receptors is not established.
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Vehicle 0.01 uM 0.05 uM 0.10 uM
PDBu PDBu PDBu
Fig. 6. Effect of phorbol dibutyrate (PDBu) on (A) 80 kDa protein
phosphorylation and (B) thromboxane receptor density in mesangial
cells. Eighty kDa phosphorylation and throinboxane receptor density in
the presence of 10 n Sq were determined as described in Methods.
Values shown are mean SE of data from 3 to 6 experiments. < 0.05
vs. DMSO vehicle alone.
0
0 2 4 6 8 10 12 14 16
[3H]-Sq bound, fmol/106 cells
Fig. 7. Effect of 0.1 tii phorbol dibutyrate (PDBu) on specific binding
and affinity of [3H]-Sq in cultured renal mesangial cells. [3H]-Sq binding
was determined as described in Methods at concentrations from 0.05 to




































PKC mediated phosphorylation of other endogenous sub-
strates, including the receptor site per Se, may be more directly
linked and quantitatively better correlated to TX receptor
down-regulation than is phosphorylation of the MARCKS pro-
tein. Although PDBu activated PKC of mesangial cells within
15 minutes, no change in Sq binding was detectable at 15
minutes or one hour (not shown). Thus, as in glomeruli, some
time lag was evident between PKC activation and a detectable
decline in TX receptors.
A representative experiment which examined specific satura-
tion binding of Sq to mesangial cells incubated with PDBu for
four hours and Scatchard transformation of this binding data is
shown in Figure 7. PDBu did not alter the affinity of the binding
sites for Sq. However, Bmax was decreased by 30% whether Sq
binding was expressed as a function of MC number, or MC
protein (Fig. 7B, Table 1).
Discussion
These results clearly show that down regulation of TX
receptor sites, as assessed from the binding of the stable TX
antagonist Sq, occurs within four hours of activation of PKC in
both freshly isolated rat glomeruli and cultured rat MC. The
down-regulation of TX receptor sites in glomeruli was observed
in association with activation of PKC induced by either PDBu
or a high concentration of glucose. Inhibition of both PKC
activation and changes in TX receptor number by the PKC
inhibitor staurosporine indicate that the action of these agents
to reduce TX receptor number was mediated by the PKC
signaling system. High glucose concentrations have now been
shown to activate PKC activity in several tissues, including
pancreatic islets [17], cultured capillary endothelial cells [18],
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MC [15, 19], and isolated glomeruli [6]. As noted above, PKC is
activated in glomeruli from SDR within one week of induction
of diabetes [61, an action mediated at least in part by enhanced
glomerular DAG formation in the presence of high ambient
glucose concentrations [7]. Recent studies have described down
regulation of receptors for angiotensin [20, 211 and TX [5] in the
kidney of diabetic rats, and of TX receptor density in platelets
from type I diabetics [22]. Whether these latter changes are
related to hyperglycemia, activation of PKC or both is not
known. However, the observation that culture of vascular
smooth muscle cells in the presence of a high glucose concen-
tration caused PKC dependent decreases in angiotensin and
vasopressin responses [23] provides additional evidence for a
link between glucose induced PKC activation and hormone
receptor down-regulation.
The density of Sq binding sites in our glomerular preparations
(Bmax of387 fmol/mg) was remarkably similar to that previously
reported for glomeruli from adult male Sprague-Dawley rats
(361 fmoL/mg [13]) and mature Wystar-Kyoto rats (361 fm/mg)
[12]. However, there are differences in the affinity of the sites
identified. The value (6.4 nM) obtained in our studies of isolated
glomeruli was intermediate to those previously reported for rat
glomeruli, that is, 3.4 nvt [12] and 14 nM [13]. Whether these
differences reflect variations in glomerular isolation procedures
and other experimental conditions, or are a function of rat strain
or sex differences is uncertain. The 30% decrease in TX
receptor density which follows PKC activation with PDBu or a
high ambient concentration of glucose is less than the 50%
decrease in endothelin receptors elicited by phorbol, 12-
myristate,13-acetate in vascular smooth muscle cells [10] or the
61% decrease in arginine vasopressin receptor sites in adrenal
glomerulosa cells exposed to PDBu [9]. It is also less than the 40
to 50% decrease in TX receptor sites reported in glomeruli
isolated from SDR by Wilkes et al [5]. The latter difference
might at least in part be a function of the time of exposure of
glomeruli to a high concentration of glucose or other activators
of glomerular PKC in the diabetic state [6]. Effects on receptor
turnover and/or internalization may be expressed to a greater
degree with more chronic PKC activation. This is suggested by
the greater reduction in TX receptor sites to 50% of control in
glomeruli incubated with 30 rn glucose for 24 hours. The
functional significance of the reduction in glomerular TX recep-
tor sites induced by PKC activation in response to glucose was
not examined in the current study, and remains speculative.
However, in previous work, Wilkes, et a! reported that the 50%
decline in glomerular TX receptor density observed in the one
to two week diabetic rat was associated with attenuation of the
in vivo actions of infused U-466l9 to reduce renal blood flow,
GFR and single nephron GFR.
TX binding sites on MC have not been previously character-
ized. At a Bmax of 15 fmolIlO6 MC, the calculated receptor
density of 9000 sites/cell is somewhat higher (5422 sites/cell)
than that reported from binding of the TX agonist ['251]-BOP to
cultured saphenous vein cells [24], and rat aortic vascular
smooth muscle cells in culture (5430 sites/cell) [25]. However,
Masuda et al reported values in aortic vascular smooth muscle
cells of 10000 to 15000 TX binding sites/cell [26]. In contrast to
the TX receptor of platelets, which has been extensively
studied [27, 28], TX receptors on cells of vascular origin are less
well-defined [29]. However, both tissue and species differences
in ligand binding to TX receptors have been documented [24,
29]. With a single, high-affinity TX binding site (Kdof 3 nM),
cultured MC provide a model to study the factors which may
regulate TX receptors, and thereby modulate the expression of
TX action on these cells.
Desensitization and down-regulation of TX receptors have
been characterized most extensively in platelets [27] and a
cultured human leukemia cell line [28]. Homologous desensiti-
zation is rapid, with down-regulation of high-affinity binding
sites occurring concurrently [28] or with a slower time course
[27]. Evidence against PKC involvement in the rapid homolo-
gous desensitization of TX receptors in platelets has been
presented [30], however, a role for PKC in TX receptor down-
regulation has not been previously evaluated directly. Glomer-
ular TX receptor desensitization and down-regulation may
differ from that described in platelets. Wilkes, et al could not
normalize [3H]-Sq binding to glomeruli from diabetic rats by
treatment with a thromboxane synthetase inhibitor which sup-
pressed urinary excretion of thromboxane [5]. Furthermore,
infusion of the thromboxane agonist U-466l9 into normal rats
did not change the number or affinity of glomerular TX receptor
sites [5]. These results suggest that heterologous factors may be
more important than homologous down-regulation of TX recep-
tor sites in the glomerulus.
Activation of PKC has now been linked to both an acute
desensitization of cellular responses to hormonal stimulation
and down-regulation of hormone receptor sites [31]. Cellular
responses to several vasoactive agents may be modulated by
the activity of PKC. Thus, endothelin binding sites in vascular
smooth muscle [4, 10, 37] and C-6 glial cells [33] are reduced by
PKC activation. Conversely, desensitization of vascular
smooth muscle to the vasoconstrictive action of vasopressin is
attenuated when PKC activity is decreased [34]. PKC activa-
tion has also been implicated in homologous desensitization of
MC to angiotensin II [8, 35]. Our studies add TX to the list of
vasoactive agents whose membrane receptors may be modified
by activation of PKC. The mechanisms by which activation of
PKC reduces TX and other hormone receptor sites is not
certain. Most extensively studied in this regard is the action of
PKC on epidermal growth factor (EGF) receptors in cultured
fibroblasts. Phosphorylation of EGF receptors by PKC is
associated with a decrease in EGF receptor number and atten-
uation of EGF action [36]. Whether direct receptor phosphory-
lation is also involved in the down-regulation of TX or other
pressor hormone binding sites induced by activation of PKC in
renal tissues remains to be determined.
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